RxDoctor Payments Data

Antonio Rivera, MD

Internal Medicine · Falls Church, VANPI 1649212978

Payments from drug & device makers

$585in general payments, 2019–2025

Across 16 payments — averaging $36.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atos Medical Inc$145
  • Rigel Pharmaceuticals, Inc.$125
  • Amgen$99
  • Mallinckrodt Enterprises LLC$75
  • Redhill Biopharma Inc.$44
  • Novo Nordisk$32
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$48383%
  • Education$10217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$585 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$150,603
Medicare patients
219
Services billed
2,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin112$133,496
OzempicSemaglutide49$63,441
JanuviaSitagliptin Phosphate38$53,509
FarxigaDapagliflozin Propanediol27$43,455
TradjentaLinagliptin33$33,681
TrulicityDulaglutide14$19,191
LinzessLinaclotide21$17,056
EliquisApixaban20$13,651
Tresiba Flextouch U-200Insulin Degludec20$9,468
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,059
Esomeprazole Magnesium29$2,959
Pantoprazole Sodium240$2,351
Levothyroxine Sodium161$1,820
Amlodipine Besylate233$1,791
Alfuzosin Hcl ErAlfuzosin Hcl71$1,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$63,44149 claims
AbbVieLinzess$16$17,05621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →